O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve ...

In this article, we will take a look at 9 Oversold Biotech Stocks to Invest In. Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value ...

The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies. The Earnings Trends report ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and profits thanks to an important cancer drug. It's developing other products ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...